Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
| Market Cap | $2.11B-27.0% |
| Revenue (ttm) | $68.23M+56.7% |
| Net Income | -$475.67M+33.5% |
| EPS | -$0.90+50.0% |
| Shares Out | 622.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,228,526.53 |
| Open | $3.44 |
| Previous Close | $3.59 |
| Day's Range | $3.27 - $3.46 |
| 52-Week Range | $2.77 - $5.24 |
| Beta | 1.03 |
| Analysts | Hold |
| Price Target | $5.90(+73.84%) |
| Earnings Date | Feb 24, 2027 |
About RXRX
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating RXRX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 24, 2027Earnings report
$RXRX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in RXRX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RXRX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RXRX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New RXRX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RXRX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in RXRX
| ARKKARK Innovation ETF | $91.42M |
| VTIVanguard Morningstar Total Stock Market ETF | $66.07M |
| XBIState Street SPDR S&P Biotech ETF | $62.98M |
| ARKGARK Genomic Revolution ETF | $59.14M |
| IWMiShares Russell 2000 ETF | $47.68M |
| VBVanguard Morningstar Small-Cap ETF | $47.30M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from RXRX’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 earnings coverage highlights clinical progress (FAP data, REC 4881 Phase 2 win) and cash runway; leadership change to Fred Hassan adds credibility. Market positioning in AI drug discovery sector su
Recent Insider Activity
Insider Score Trend Over Time
-44.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.